Targeted pill shows promise for chinese lung cancer patients with rare gene change
NCT ID NCT04677595
First seen Apr 07, 2026 · Last updated May 17, 2026 · Updated 9 times
Summary
This study tested an oral targeted drug called capmatinib in 36 Chinese adults with advanced non-small cell lung cancer that has a specific MET gene mutation (exon 14 skipping). The drug aims to block cancer growth by targeting this faulty gene. Researchers measured how many patients had their tumors shrink or disappear, and how long that effect lasted.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Xiamen, Fujian, 361001, China
-
Novartis Investigative Site
Foshan, Guangdong, 528000, China
-
Novartis Investigative Site
Guangzhou, Guangdong, 510080, China
-
Novartis Investigative Site
Guangzhou, Guangdong, 510515, China
-
Novartis Investigative Site
Guangzhou, Guangdong, 524000, China
-
Novartis Investigative Site
Harbin, Heilongjiang, 150000, China
-
Novartis Investigative Site
Zhengzhou, Henan, 450003, China
-
Novartis Investigative Site
Wuhan, Hubei, 430024, China
-
Novartis Investigative Site
Shenyang, Liaoning, 110001, China
-
Novartis Investigative Site
Jinan, Shandong, 250117, China
-
Novartis Investigative Site
Shanghai, Shanghai Municipality, 200030, China
-
Novartis Investigative Site
Chengdu, Sichuan, 610041, China
-
Novartis Investigative Site
Kunming, Yunnan, 650106, China
-
Novartis Investigative Site
Hangzhou, Zhejiang, 310022, China
-
Novartis Investigative Site
Beijing, 100142, China
-
Novartis Investigative Site
Shanghai, 200030, China
-
Novartis Investigative Site
Tianjin, 300052, China
Conditions
Explore the condition pages connected to this study.